1. Home
  2. SCYX vs ACCL Comparison

SCYX vs ACCL Comparison

Compare SCYX & ACCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$3.79

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

Logo Acco Group Holdings Limited Ordinary Shares

ACCL

Acco Group Holdings Limited Ordinary Shares

N/A

Current Price

$2.54

Market Cap

36.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
SCYX
ACCL
Founded
1999
2009
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
36.3M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
SCYX
ACCL
Price
$3.79
$2.54
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $36.33
N/A
AVG Volume (30 Days)
★ 284.7K
5.6K
Earning Date
11-09-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.36
N/A
EPS
N/A
★ N/A
Revenue
★ $257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$977.86
N/A
P/E Ratio
★ N/A
$17.13
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.23
52 Week High
$6.09
$5.00

Technical Indicators

Market Signals
Indicator
SCYX
ACCL
Relative Strength Index (RSI) 39.78 45.52
Support Level $3.53 $2.41
Resistance Level $4.30 $3.07
Average True Range (ATR) 0.23 0.21
MACD -0.02 0.00
Stochastic Oscillator 23.92 54.43

Price Performance

Historical Comparison
SCYX
ACCL

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About ACCL Acco Group Holdings Limited Ordinary Shares

Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.

Share on Social Networks: